MarketCap
Facebook
X
TelegramBiofrontera AG Retained Earnings 2011-2026 | BFRA
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Biofrontera AG
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| -166 M | -153 M | -145 M | -137 M | -120 M | -110 M | -98.6 M | -87.9 M | -79.8 M | -75.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -75.7 M | -166 M | -117 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B |  USA |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B |  France |
 |
Autolus Therapeutics plc
AUTL
|
-1.39 B | $ 1.36 | -2.52 % | $ 362 M |  Britain |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
DBV Technologies S.A.
DBVT
|
-393 M | $ 20.25 | -0.54 % | $ 2.83 B | France |
 |
Dyadic International
DYAI
|
-93.5 M | $ 0.87 | 0.59 % | $ 31.5 M | USA |
 |
Alterity Therapeutics Limited
ATHE
|
-182 M | $ 3.78 | 4.83 % | $ 9.09 B |  Australia |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Aytu BioScience
AYTU
|
-334 M | $ 2.6 | -2.26 % | $ 16.3 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
Fate Therapeutics
FATE
|
-1.53 B | $ 1.14 | -4.2 % | $ 135 M | USA |
 |
Forte Biosciences
FBRX
|
-223 M | $ 26.44 | - | $ 342 M | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M |  Canada |
 |
Fennec Pharmaceuticals
FENC
|
-229 M | $ 6.16 | -4.05 % | $ 176 M | USA |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
Amicus Therapeutics
FOLD
|
-2.77 B | $ 14.46 | 0.03 % | $ 4.46 B | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Fulcrum Therapeutics
FULC
|
-594 M | $ 7.57 | -3.32 % | $ 480 K | USA |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Galectin Therapeutics
GALT
|
-433 M | $ 2.28 | -11.13 % | $ 146 M | USA |
 |
Gilead Sciences
GILD
|
13.7 B | $ 138.34 | -1.28 % | $ 172 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
-200 M | $ 0.54 | 4.28 % | $ 503 K |  Israel |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Genmab A/S
GMAB
|
7.11 B | $ 27.14 | -2.2 % | $ 17 B |  Danmark |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
BioNTech SE
BNTX
|
-410 M | $ 88.2 | -3.37 % | $ 27.2 B | Germany |
 |
Gossamer Bio
GOSS
|
-1.44 B | $ 0.32 | -7.11 % | $ 73.1 M | USA |
 |
Coherus BioSciences
CHRS
|
-1.38 B | $ 1.62 | -3.29 % | $ 190 M | USA |
 |
Grifols, S.A.
GRFS
|
619 M | $ 7.98 | -3.04 % | $ 6.83 B |  Spain |
 |
Akari Therapeutics, Plc
AKTX
|
-265 M | $ 3.5 | -1.13 % | $ 236 B | Britain |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
GT Biopharma
GTBP
|
-724 M | $ 0.41 | -8.56 % | $ 2.26 M | USA |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
-6.7 B | $ 316.69 | -4.13 % | $ 41.5 B | USA |
 |
Halozyme Therapeutics
HALO
|
54.8 M | $ 63.72 | 1.01 % | $ 7.64 B | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
-401 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Harmony Biosciences Holdings
HRMY
|
161 M | $ 27.53 | -0.67 % | $ 1.58 B | USA |
 |
Atreca
BCEL
|
-457 M | - | -11.76 % | $ 5.79 M | USA |